 NEW YORK--BUSINESS WIRE--WaterMill Asset Management Corp. together with its affiliates, WaterMill or we, which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3 of the outstanding shares of Ziopharm Oncology, Inc. NASDAQ: ZIOP Ziopharm or the Company, today released a 55-page presentation that details the case for urgent change in the boardroom and summarizes its director candidates value-enhancing vision. As a reminder, W 